ClinicalTrials.gg
CompletedNCT03372239Updated May 28, 2020

Oral Bioavailability,and Food Effect Study and Single Ascending Dose PK Study in Healthy Male Volunteers

A Phase 1 interventional study of Indoximod base formulation and Indoximod HCL (salt) formulation in Healthy, sponsored by NewLink Genetics Corporation. Completed at 1 site in Canada. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-05-28.

Sponsored by NewLink Genetics Corporation · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Jan 2018, 8 years 9 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
Male
01

Study summary

This 2-part study will assess the effect of formulation and food on the pharmacokinetics of Indoximod in healthy volunteers. Part 1 is an open-label, 3-period, 6-sequence study. Participants will receive single doses of Indoximod base or salt formulation, in the fasted or fed state. Part 2 is a randomized single ascending dose study of indoximod salt formulation to characterize the PK profile and determine the safety and tolerability of each dose in healthy male volunteers.

02

Conditions studied

  • Healthy

Keywords

  • Indoximod
03

In context

Lead sponsor

NewLink Genetics Corporation is the lead sponsor of 34 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male subjects 18 to 55 years of age, inclusive.
  • (BMI) of 18.0 to 30.0 kg/m2, and a minimum weight of 50.0 kg.
  • Non-smoker for at least 3 months prior to Screening.
  • Male subjects with female sexual partners of must be using and willing to continue using medically acceptable
  • Signed and dated written

Exclusion criteria

Exclusion Criteria:

  • History or presence of any abnormality, illness, or disease which, in the opinion of the investigator, may either put the subject at risk because of participation in the study or influence the validity of the results of the study.
  • Subjects with conditions, inflammatory bowel disease, rheumatoid arthritis, and/or subjects who have undergone an organ transplant.
  • Self-reported history of substance or alcohol dependence within the past 2 years, and/or has ever participated or plans to participate in a substance or alcohol rehabilitation program to treat their substance or alcohol dependence.
  • Any medical/surgical procedure or trauma within 4 weeks of the first study drug administration or planned within 1 month of study completion.
  • Positive urine drug screen.
  • Positive breath alcohol test.
  • Evidence of clinically significant hepatic or renal impairment
  • Inability to fast for a minimum of 14 hours.
  • Inability to swallow large capsules/tablets.
  • Positive for , , or (HIV).
  • Donation or loss of more than 500 mL whole blood within 1 month preceding entry into the Treatment phase and throughout the study.
  • Difficulty with venous access or unsuitable or unwilling to undergo catheter insertion.
  • History of severe allergic reaction (including anaphylaxis) to any substance, or previous status asthmaticus.
  • Treatment with an drug within 5 times the elimination half-life, if known (eg, a marketed product), or within 30 days (if the elimination half-life is unknown) prior to first drug administration or is concurrently enrolled in any research judged not to be scientifically or medically compatible with this study.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
48 participants (actual)

Study arms

  • Experimental
    Part 1: Bioavailability and Food Effect

    Subjects will be randomized to receive the following 3 regimens in randomized sequence: 1. Single dose of Indoximod base formulation under fasting conditions 2. Single dose of Indoximod HCL (salt) formulation under fed conditions 3. Single dose of Indoximod HCL (salt) formulation under fasting conditions

    Drug: Indoximod base formulation · Drug: Indoximod HCL (salt) formulation · Other: Placebo

  • Experimental
    Part 2: Single Ascending Dose

    Drug: Indoximod HCL (salt) formulation · Other: Placebo

Interventions

  • DrugIndoximod base formulation

    Specified dose on specified days

  • Specified dose on specified days

  • OtherPlacebo

    Specified dose on specified days

06

What researchers measure

Primary outcomes

  1. Area Under the Plasma Concentration-Time Curve

    Part 1 (Food Effect)

    Time frame: up to 20 Days

  2. Pharmacokinetics: Serum concentrations (Cmax/Steady State)

    Part 1 (Food Effect)

    Time frame: up to 20 Days

  3. Pharmacokinetics: Serum concentrations (Cmax/Steady State)

    Part 2 (Single rising dose)

    Time frame: up to 4 Days

Secondary outcomes

  1. Percentage of patients with adverse events

    Part 1

    Time frame: up to 34 Days

  2. Percentage of patients with adverse events

    Single rising dose

    Time frame: up to 16 Days

07

Study locations

1 site
  • INC Research/inVentiv Health
    Toronto, Ontario, Canada
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2017 to primary completion in Jan 2018, 2 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 10, 2017
First posted
Dec 13, 2017
StartActual
Nov 21, 2017
Primary completionActual
Jan 25, 2018
CompletionActual
Apr 16, 2018
Last update
May 28, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 28, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03372239
Responsible party
Sponsor
First posted
Dec 13, 2017
Start date
Nov 21, 2017
Primary completion
Jan 25, 2018
Completion
Apr 16, 2018
Last update
May 28, 2020

Study contacts

Eugene Kennedy, MD
study director · NewLink Genetics Inc

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sodium Chloride

Start the discussion